Evidence map›Paper›PMID 34491549›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2021

Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8

Hailin Zhang, Yonghui Zhang, Jie Dong, Shuguang Zuo, Gang Meng, Junhua Wu, Jiwu Wei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hailin Zhang *Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, 22 Hankou Road, Nanjing, 210093, China.
Yonghui Zhang *Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, 22 Hankou Road, Nanjing, 210093, China.
Jie Dong *Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, 22 Hankou Road, Nanjing, 210093, China.
Shuguang ZuoJiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, 22 Hankou Road, Nanjing, 210093, China.
Gang MengJiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, 22 Hankou Road, Nanjing, 210093, China.
Junhua WuJiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, 22 Hankou Road, Nanjing, 210093, China. wujunhua@nju.edu.cn.
Jiwu WeiJiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, 22 Hankou Road, Nanjing, 210093, China. wjw@nju.edu.cn.ORCID http://orcid.org/0000-0002-0883-1824

Funding

Jiangsu Key Laboratory for the Research and Utilization of Plant Resources BE2018701National Natural Science Foundation of China 81472820National Natural Science Foundation of China 81700037National Natural Science Foundation of China 81773255National Natural Science Foundation of China 81972888
6 · The paper itself

Abstract

purposeTreatment-associated upregulation of suppressive checkpoints and a lack of costimulatory signals compromise the antitumor efficacy of oncolytic virus immunotherapy. Therefore, we aimed to identify highly effective therapeutic targets to provide a proof-of-principle for immune checkpoint together with oncolytic virus-mediated viro-immunotherapy for cancer.

methodsA fusion protein containing both the extracellular domain of programmed death-1 (PD-1) and the poliovirus receptor (PVR) was designed. Next, the corresponding expression fragment was inserted into the genome of a replication-competent adenovirus to generate Ad5sPD1PVR. The infection, expression, replication and oncolysis of Ad5sPD1PVR were investigated in hepatocellular carcinoma (HCC) cell lines. Immune activation and the antitumor efficacy of Ad5sPD1PVR were examined in HCC tumor models including a humanized immunocompetent mouse model.

resultsAd5sPD1PVR effectively infected and replicated in HCC cells and secreted sPD1PVR. In a H22 ascitic HCC mouse model, intraperitoneal injection of Ad5sPD1PVR markedly recruited lymphocytes and activated antitumor immune responses. Ad5sPD1PVR exerted a profound antitumor effect on ascitic HCC. Furthermore, we found that Ad5sPD1PVR-H expressing sPD1PVR of human origin exhibited potent antitumor effects in a HCC humanized mouse model. We also found that CD8

conclusionsFrom our data we conclude that the newly designed recombinant Ad5sPD1PVR virus significantly enhances CD8

Indexed as

Immunologic SurveillanceAdenoviridaeAnimalsAntineoplastic AgentsAscitesCarcinoma, HepatocellularCD8-Positive T-LymphocytesCell Line, TumorDisease Models, AnimalImmunosuppression TherapyInflammationLiver NeoplasmsLymphocyte ActivationLymphocytes, Tumor-InfiltratingMaleMiceAntineoplastic AgentsfludarabineRecombinant Fusion ProteinsVidarabineFludarabineHepatocellular carcinomaOncolytic virusPD-1/PD-L1PVR/CD155T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT)

Identifiers

PMID34491549
PMCPMC12980736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.